Blood Glucose MonitorsType IIType II DiabetesDiabetes & EndocrinologyFamily PracticeInternal MedicineGeriatricsGlucose MonitorsDiabetesType 2 DiabetesPublic HealthSide Effects
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Feb. 21, 2020 (HealthDay News) -- A higher proportion of older and multimorbid patients with type 2 diabetes achieve low hemoglobin A1c (HbA1c) levels, according to a study published online Feb. 19 in BMJ Open Diabetes Research & Care.
Rozalina G. McCoy, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined patterns of glycemic control among 194,157 adults with type 2 diabetes. Comorbidity burden was assessed based on 16 comorbidities, classified as diabetes concordant (diabetes complications or risk factors), discordant (unrelated to diabetes), or advanced (life limiting).
The researchers found that 45.2, 30.6, 2.7, and 13 percent had only concordant comorbidities, concordant and discordant comorbidities, only discordant comorbidities, and one or more advanced comorbidity, respectively. The mean HbA1c was 7.7 percent among those aged 18 to 44 years versus 6.9 percent in those aged ≥75 years, and it was lower among those with comorbidities: 7.3, 7.1, 7.1, and 7.0 for those with concordant-only, discordant-only, concordant and discordant, and advanced comorbidities, respectively, versus 7.4 percent among those without comorbidities. With age, there was a decrease in the odds of insulin use (odds ratio [OR], 0.51 for age ≥75 versus 18 to 44 years); an increase in the odds was seen with accumulation of concordant (OR, 5.50 for at least three versus none), discordant (OR, 1.72 for at least three versus none), and advanced (OR, 1.45 for at least two versus none) comorbidities.
"Our study suggests ample opportunity for treatment deintensification among older patients and patients with advanced and/or multiple comorbidities," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 26, 2022
Read this Next
Other Trending Articles